共 50 条
DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes
被引:22
作者:
Kusunoki, M.
[1
]
Sato, D.
[2
]
Nakamura, T.
[2
]
Oshida, Y.
[3
]
Tsutsui, H.
[4
]
Natsume, Y.
[5
]
Tsutsumi, K.
[6
]
Miyata, T.
[7
]
机构:
[1] Aichi Med Univ, Dept Internal Med, Med Clin, Nagoya, Aichi 4610005, Japan
[2] Yamagata Univ, Grad Sch Med Sci, Dept Biomed Informat Engn, Yamagata 990, Japan
[3] Nagoya Univ, Res Ctr Hlth Phys Fitness & Sports, Nagoya, Aichi 4648601, Japan
[4] Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Tokyo 173, Japan
[5] Nagoya Univ, Grad Sch Med, Dept Sports Med, Nagoya, Aichi 4648601, Japan
[6] Okinaka Mem Inst Med Res, Tokyo, Japan
[7] Sanno Med Ctr, Vasc Ctr, Tokyo, Japan
关键词:
teneligliptin;
dipeptidyl peptidase-4 inhibitor;
insulin resistance;
HDL-cholesterol;
triglyceride;
D O I:
10.1055/s-0034-1390419
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to improve the glycemic control and blood hemoglobin A(1c) (HbA(1c)) concentrations. However, there are few reports as yet suggesting that DPP-4 inhibitors may also improve insulin resistance and the serum lipid profile in the clinical setting. This study was aimed at investigating the effect of 14-week treatment with teneligliptin (20mg/day) on the homeostasis model assessment ratio (HOMA-R), an indicator of insulin resistance, and serum lipid profile in 9 patients with type 2 diabetes. The treatment produced a significant decrease of the blood glucose and HbA(1c) concentration (blood glucose: p=0.008; HbA(1c): p=0.038), and also improved HOMA-R (p=0.039). Furthermore, the patients showed elevation of the serum HDL-cholesterol level (p=0.032), and a tendency towards reduction of the serum triglyceride level. The results indicate that teneligliptin acts not only to improve the blood glucose control, but also to improve the insulin resistance and serum lipid profile in Japanese type 2 diabetes patients.
引用
收藏
页码:532 / 534
页数:3
相关论文
共 50 条